Nikoletta Skarmoutsou

Nikoletta Skarmoutsou

Auto-generated profile, based on publicly available information

Nikoletta Skarmoutsou

Department of Biopathology, Sismanogleio General Hospital, Athens, Greece

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2021 in Healthcare Informatics Research
Verified
Journal Article
Open access
PDF file
GEORGIOS FERETZAKISGEORGIOS FERETZAKIS
GEORGIOS FERETZAKIS
ASAikaterini Sakagianni
Aikaterini Sakagianni
ELEvangelos Loupelis
Evangelos Loupelis
Dimitris KallesDimitris Kalles
Dimitris Kalles
NSNikoletta Skarmoutsou
Nikoletta Skarmoutsou
EDEvangelos Dimitrellos
Evangelos Dimitrellos
Objectives: In the era of increasing antimicrobial resistance, the need for early identification and prompt treatment of multi-drug-resistant infections is crucial for achieving favorable outcomes in critically ill patients. As traditional microbiological susceptibility testing requires at least 24 hours, automated machine learning (AutoML) techniques could be used as clinical decision support tools to predict antimicrobial resistance and select appropriate empirical antibiotic treatment.Methods: An antimicrobial susceptibility dataset of 11,496 instances from 499 patients admitted to the internal medicine wards of a public hospital in Greece was processed by using Microsoft Azure AutoML to evaluate antibiotic susceptibility predictions using patients’ simple demographic characteristics, as well as previous antibiotic susceptibility testing, without any concomitant clinical data. Furthermore, the balanced dataset was also processed using the same procedure. The datasets contained the attributes of sex, age, sample type, Gram stain, 44 antimicrobial substances, and the antibiotic susceptibility results.Results: The stack ensemble technique achieved the best results in the original and balanced dataset with an area under the curve-weighted metric of 0.822 and 0.850, respectively.Conclusions: Implementation of AutoML for antimicrobial susceptibility data can provide clinicians useful information regarding possible antibiotic resistance and aid them in selecting appropriate empirical antibiotic therapy by taking into consideration the local antimicrobial resistance ecosystem.

29 July 2026 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
AOAmaury O’JEanson
Amaury O’JEanson
ENElisabet Nielsen
Elisabet Nielsen
ZAZoe Athanassa
Zoe Athanassa
AGAghavni Ginosyan
Aghavni Ginosyan
KIKonstantinos Ioannidis
Konstantinos Ioannidis
LFLena E. Friberg
Lena E. Friberg
To characterise the pharmacokinetics (PK) of ceftazidime-avibactam (CAZ-AVI) and explore the dynamics of a broad blood immune biomarker panel in critically ill patients with hospital-acquired (HAP) or ventilator-associated pneumonia (VAP) caused by Klebsiella pneumoniae. Population PK (PopPK) models were developed for CAZ and AVI individually and jointly, evaluating covariate effects and correlations at interindividual (IIV) and residual unexplained variability (RUV) levels. Biomarker turnover dynamics in blood were modelled, and exposure-biomarker relationships were assessed. The dataset included 266 drug plasma concentration measurements and 48-87 observations per biomarker, collected from ten critically ill patients. CAZ and AVI PK were well-described by two-compartment models, with estimated creatinine clearance (eCrCL) as a key covariate on clearance. Joint modelling revealed significant correlations between the two drugs at both IIV and RUV levels, supporting coherent patient-specific simulations. Turnover dynamics were characterised for 32 biomarkers. The most pronounced biomarker changes over the course of treatment were decreases in IL6, CRP, and AREG, and increases in DCBLD2, LAMP3, and TRIM21. A significant exposure-response relationship was identified between CAZ plasma concentrations and CRP turnover, with higher CAZ levels associated with inhibition of CRP production. The joint PopPK model confirmed eCrCL as a key covariate for clearance. Changes in 32 immune response biomarkers were quantified, with CRP showing a clear exposure-response relationship. These findings provide a foundation for prioritising biomarkers for future studies to guide therapeutic strategies in critically ill patients with HAP or VAP.